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Abstract
Background: Atherosclerosis affects aorta, coronary, carotid, and iliac arteries most frequently than any
other body vessel. There may be common molecular pathways sustaining this process. Plaque presence
and diffusion is revealed by circulating factors that can mediate systemic reaction leading to plaque rupture
and thrombosis.
Results: We used DNA microarrays and meta-analysis to study how the presence of calcified plaque
modifies human coronary and carotid gene expression. We identified a series of potential human
atherogenic genes that are integrated in functional networks involved in atherosclerosis. Caveolae and
JAK/STAT pathways, and S100A9/S100A8 interacting proteins are certainly involved in the development
of vascular disease. We found that the system of caveolae is directly connected with genes that respond
to hormone receptors, and indirectly with the apoptosis pathway.
Cytokines, chemokines and growth factors released in the blood flux were investigated in parallel. High
levels of RANTES, IL-1ra, MIP-1alpha, MIP-1beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-17, PDGF-BB, VEGF and IFN-
gamma were found in plasma of atherosclerotic patients and might also be integrated in the molecular
networks underlying atherosclerotic modifications of these vessels.
Conclusion: The pattern of cytokine and S100A9/S100A8 up-regulation characterizes atherosclerosis as
a proinflammatory disorder. Activation of the JAK/STAT pathway is confirmed by the up-regulation of IL-
6, STAT1, ISGF3G and IL10RA genes in coronary and carotid plaques. The functional network constructed
in our research is an evidence of the central role of STAT protein and the caveolae system to contribute
to preserve the plaque. Moreover, Cav-1 is involved in SMC differentiation and dyslipidemia confirming
the importance of lipid homeostasis in the atherosclerotic phenotype.
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Background
Atherosclerosis is a chronic inflammatory disease of the
arterial wall, where both innate and adaptive immuno-
logic and inflammatory mechanisms are involved. Several
genomic approaches have been applied to understand this
paradigmatic multifactorial disease: these include DNA
polymorphisms and candidate gene searching, transcrip-
tome and proteome analysis[1]. In particular, over the
past few years, a number of studies have analyzed gene
expression profiles in plaques from autopsy and sur-
gery[2], symptomatic and asymptomatic patients[3], sta-
ble and unstable plaques[4] as well as in mouse models
for atherosclerosis[5]. King et al.[6] analyzed differences
in gene expression between plaques of different patholog-
ical grade and Satterthwaite et al.[7] used gene expression
data to identify genes related to inflammation in athero-
sclerotic coronaries from ischemic heart and dilated cardi-
omyopathy. Both these studies as those previously cited,
aimed to single out risk factors in one definite condition
and tissue. Instead, we decided to adopt an approach
where experimental gene expression data are integrated by
metanalysis and blood protein measurements to analyze
a wider range of pathological samples and patients and to
obtain a larger picture of gene/protein interactions
involved in atherosclerotic process. The interactions
found with our work are common to plaques of different
vessel location. Interestingly, no study has so far investi-
gated in humans the relationship between plaque gene
expression and released circulating factors, but analyzed
in association with platelet aggregation in patients under-
going percutaneous intervention[8] that cause blood flux
impairment and modulate the inflammatory response.
Using high throughput approaches, we analyzed released
cytokines and growth factors in the arterial blood of
atherosclerotic patients presenting 75% coronary stenosis
at least. These experimental data have been used simulta-
neously for two aims: a) confirmation of specific gene
expression results and b) completion of specific altered
pathways identified by gene expression analysis. In paral-
lel, we applied DNA microarray and quantitative real-time
PCR (qRT-PCR) to identify differentially expressed genes
in coronaries with same stenosis and calcified plaque. In
our study we used samples derived from whole atheroscle-
rotic biopsies: atherosclerosis is, in fact, the result of path-
ological interactions of multiple cell types, mediated by
body fluids, hence, cell-based studies will only reveal a
subset of these interactions. We also applied meta-analy-
sis to correlate the profiles of atherosclerotic coronaries to
other profiles obtained in carotids with comparable sten-
osis. This work has led us to the identification of pleio-
tropic and epistatic gene interactions and of pathways that
appear to contribute to preserve the plaque, but also to
enhance the physiological processes sustaining/attenuat-
ing its systemic effects. This information has been useful
to define molecular networks underlying the atheroscle-
rotic condition. Our findings may have significance for
the development of pharmacological approaches against
the central nodes of the identified network, for the pre-
vention or attenuation of atherosclerosis effects on
human health.
Results
The traits of patients (PT) that have been analyzed in this
study are reported in Table 1, and the use of samples
obtained from them is summarized in Figure 1a. We pro-
duced gene expression profiles from 8 atherosclerotic LAD
coronaries presenting at least 75% stenosis at angiography
(PT 1–8), and compared with the profile of a pool made
of 10 normal LAD coronaries (PT 9–18). Histochemical
analysis on coronary samples shows calcified plaque in
the patient samples, while no atherosclerotic tissue was
found in controls (Figure 1b). According to the American
Heart Association (AHA) classification[9] 71.4% of the
patients presented plaques of type VII and 28.6% pre-
sented type VI plaques. Moreover, 76% of the coronary
ischemic patients presented a hypertension status, accord-
ing to the European Society of Hypertension/European
Society of Cardiology[10] or were treated with antihyper-
tensive drugs. Since atherosclerosis generally affects other
vessels (aorta, carotid and iliac arteries), we used datasets
available in public databases and compared 8 expression
profiles of atherosclerotic carotids (PR 32–39) with the
profiles of 6 normal coronary controls (PR 40–45). Also
75% of the patients with ischemic carotids presented a
hypertension condition. We selected datasets derived
from carotids with a stenosis that was comparable to LAD
coronary samples. The general results obtained by this
series of analysis are summarized in Table 2, whereas the
detailed lists of differentially expressed genes in the
atherosclerotic samples have been deposited and are
available at GEO database (GSE11138). Comparing the
datasets of the various samples, we obtained a group of
common differentially expressed genes that we would like
to define as human "atherogenes" (see Additional file 1,
Table S2).
Finally, we measured cytokines and growth factors in the
arterial blood of 6 patients, whose gene expression pro-
files had already been produced (PT 2–7), and of a group
of 13 independent atherosclerotic patients with compara-
ble stenosis of the coronaries (PT 19–31), to associate the
atherosclerotic signals released in the blood to plaque
presence. Data on blood circulating factors were related to
those of 6 control individuals (PT 9–14). This study dem-
onstrated significant alterations of 9 interleukins, 2
growth factors and 2 chemokines in all atherosclerotic
samples (Figure 2).
To identify and characterize common molecular impair-
ments in atherosclerotic samples, we studied the lists ofBMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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atherogenes and blood-released factors and grouped them
in functionally related classes and pathways that are
described further. In many cases, the alteration of impor-
tant elements of pathways has been validated by qRT-
PCR.
Extracellular matrix (ECM) and smooth muscle cells 
(SMC)
Many genes that are down-regulated in coronary and
carotid plaques codify proteins of ECM (see Additional
file 2, Figure S1). Collagen genes of type IV, VIII, XVIII,
XIV and XXI are down-regulated in coronary and type XIV
in carotid plaque. We also evidenced the down-regulation
of a group of SMC-specific genes in both atherosclerotic
vessels such as actin-alpha 2, PDLIM5 and Cysteine and
glycine-rich protein 2 (CSRP2).
Lipid homeostasis
Interestingly, 5% of differentially expressed genes in LAD
atherosclerotic coronaries are implicated in pathologies
characterized by chronic hypertension. Since hyperten-
sion is often associated with dyslipidemias[11], we have
clustered differentially expressed genes involved in lipid/
cholesterol homeostasis and reconstructed the interaction
map shown in Figure 3. We found up-regulation of ApoE
gene in atherosclerotic coronaries and carotids, whereas
ApoC2 and ApoC1 (components of the chylomicrons,
VLDL and high-density lipoprotein (HDL)) are up-regu-
lated in the carotids only. On entering circulation, triglyc-
erides are hydrolyzed by lipoprotein lipase (LPL) and the
resulting products are taken up by interaction of ApoE
with LDL receptor or LRP. We detected down-regulation
of LPL gene in atherosclerotic patients by microarray and
confirmed it by qRT-PCR. Fatty acids produced by LPL
activity are removed from circulation by CD36[12], but
we identified down-regulation of this gene both by micro-
arrays and qRT-PCR. MSR1, another scavenger receptor,
was down-regulated in LAD coronaries. Low abundance
of atheroprotective HDL, in response to up-regulated
phospholipid transfer protein (PLTP) may be balanced by
a major uptake of the atherogenic LDL. APOER gene is up-
regulated and also ABC transporter genes are deregulated.
Finally, we evidenced the up-regulation of the liver ×
receptor (LXR).
Caveolae system
We evidenced the down-regulation of the Cav-1 and the
related Cav-2 gene in coronary samples. Cav-2 gene
down-regulation has also been confirmed in the athero-
sclerotic carotids. It is known that angiogenic factors such
as VEGF induce down-regulation of caveolin-1 and, as
matter of fact, VEGF was up-regulated in both coronary
and carotid plaque. To confirm this result we measured
VEGF mRNA by qRT-PCR evidencing 1.52 fold over-
expression in patients versus controls. Moreover, the
a) Venn diagram representing the use of biological samples  obtained from the cohort of patients recruited in our study Figure 1
a) Venn diagram representing the use of biological 
samples obtained from the cohort of patients 
recruited in our study. Yellow indicates LAD coronary 
samples used for gene expression profiling and red indicates 
arterial blood samples subjected to blood cytokine analysis. 
Intersection between red and yellow areas defines patients 
from whom coronary and blood samples have been sub-
jected to the respective analyses. b) Histological cross-sec-
tions of two control (A, B, and C, D enlargements) and two 
patient (E, F) coronary samples. A and B images show normal 
coronary walls while E and F, representative for all analyzed 
patients, evidence calcified plaque.BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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Table 1: Patient recruited (PT) and expression datasets retrieved (PR) for this study.
Patient (PT)/
Profile (PR)
Sex Age (Years) Tissue sample Pathology/
Lesion type
Co-morbidities Pharmacological 
therapy
Plasma lipid/
Stenosis/ICR
PT1 M 50 LAD Ischemic/VII Hypothyroidism D;AAP;AC;HYR +/> 75%/5
PT2 F 68 LAD;AB Ischemic/VII None D;AC +/> 75%/4.6
PT3 M 66 LAD;AB Ischemic/VII Cholecystectomy AAP;HYR =/> 75%/5
PT4 M 64 LAD;AB Ischemic/VII None D;HYR +/> 75%/5.2
PT5 M 64 LAD;AB Ischemic/VI PAH D;ST;AAP;HYR +/> 75%/4.9
PT6 M 42 LAD;AB Ischemic/VII None D;HYR +/> 75%/5.3
PT7 M 53 LAD;AB Ischemic/VII Stone Kidney D;HYR;AAP +/> 75%/5.1
PT8 M 68 LAD Ischemic/VI None D;HYR;AAP +/> 75%/5.2
PT9 M 46 LAD;AB DCM/ctrl None D;AC +/-/4.6
PT10 M 48 LAD;AB DCM/ctrl Kidney pathology D;AC =/-/4.7
PT11 F 55 LAD;AB DCM/ctrl Thyroidectomy D;AC;CDR =/-/4.5
PT12 F 59 LAD;AB DCM/ctrl None BB;AC;AAP =/-/3.2
PT13 M 63 LAD;AB DCM/ctrl None ACEH;D;AC =/-/3.6
PT14 M 53 LAD;AB DCM/ctrl None ACEH;D;AAP +/-/3.8
PT15 M 62 LAD DCM/ctrl Gilbert's 
syndrome
AAP =/-/3.5
PT16 M 61 LAD DCM/ctrl None ACEH;ST =/-/3.5
PT17 F 59 LAD DCM/ctrl None ACEH;AC;AAP =/-/4.3
PT18 F 41 LAD DCM/ctrl None D =/-/3.9
PT19 M 70 AB Ischemic/VII T2D D;HYR;SI +/> 75%/5
PT20 M 67 AB Ischemic/VII Mitral insufficiency None =/> 75%/4.3
PT21 F 82 AB Ischemic/VII HY None +/> 75%/4.6
PT22 M 63 AB Ischemic/VI None None =/> 75%/4.8
PT23 M 75 AB Ischemic/VI None ACEH;HYR +/> 75%/5.2
PT24 M 64 AB Ischemic/VII PD HYR;D;LD +/> 75%/5.1
PT25 M 75 AB Ischemic/VII T2D;HY SI;HYR +/> 75%/5.2
PT26 M 57 AB Ischemic/VII T2D;HY SI;HYR +/> 75%/5.5
PT27 M 66 AB Ischemic/VII HY HYR +/> 75%/5.2BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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PT28 M 69 AB Ischemic/VII HY HYR +/> 75%/5
PT29 M 51 AB Ischemic/VI None None =/> 75%/4.8
PT30 F 78 AB Ischemic/VII HY HYR +/> 75%/4.5
PT 31 M 75 AB Ischemic/VI None None =/> 75%/5.1
PR32* M 67 Carotid Ischemic Acute bronchitis NA NA/75%/NA
PR33* M 67 Carotid Ischemic Acute bronchitis NA NA/71%/NA
PR34* F 63 Carotid Ischemic CAD;T2D;HY NA NA/75%/NA
PR35* F 63 Carotid Ischemic CAD;T2D;HY NA NA/50%/NA
PR36* F 59 Carotid Ischemic HY;HYCH NA NA/75%/NA
PR37* F 59 Carotid Ischemic HY;HYCH NA NA/83%/NA
PR38* F 71 Carotid Ischemic CAD;T2D;HY;HY
CH;AD
NA NA/70%/NA
PR39* F 71 Carotid Ischemic CAD;T2D;HY;HY
CH;AD
NA NA/83%/NA
PR40† NA NA Coronary Normal NA NA NA
PR41† NA NA Coronary Normal NA NA NA
PR42† NA NA Coronary Normal NA NA NA
PR43‡ M NA Coronary Normal NA NA NA
PR44‡ M NA Coronary Normal NA NA NA
PR45‡ M NA Coronary Normal NA NA NA
* PR of atherosclerotic carotids from E-MEXP-268, a study performed on carotid bilateral stenosis in which the two carotids (indicated by couple 
of consecutive numbers in the Table) of four independent patients have been analyzed. † PR of normal coronaries from GSE3526 (GSM80609, 
GSM80610, GSM80631). ‡ PR of normal coronaries from GSE7307 (GSM176115, GSM175820, GSM175821). ICR: index of cardiovascular risk; 
LAD: Left Anterior Descendent Coronary; AB: Arterial Blood; DCM/ctrl: Dilated Cardiomyopathy, used as pooled controls for microarray 
experiments; D: Diuretics; AAP: Anti-arrhythmics; AC: Anti-coagulants; HYR: Hypertension regulators; BB: Beta-blockers; ACEH: ACE inhibitors; 
ST: Statins; CDR: Cholesterol down-regulators; SI: Synthetic insulin; LD: Levodopa; PAH: Pulmonary hypertension; T2D: Type-2-diabetes; HY: 
Hypertension; HYCH: Hypercholesterolemia; PD: Parkinson's disease; AD: Artery disease; NA: not available.
Table 1: Patient recruited (PT) and expression datasets retrieved (PR) for this study. (Continued)
Table 2: Summary of genes differentially expressed in atherosclerotic vessels.
Tissue % Up-regulated genes % Down-regulated genes Total number of deregulated genes
LAD-specific 34.31 65.69 953
Carotid-specific 53.40 46.60 1736
Common 39.75 60.25 161BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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Concentration of cytokines, chemokines and GFs differentially (p ≤ 0.05) expressed in arterial blood of patients Figure 2
Concentration of cytokines, chemokines and GFs differentially (p ≤ 0.05) expressed in arterial blood of 
patients. Baseline indicates mean values concentration across patients or controls for each protein. RANTES concentration is 
not shown, since measured values in patient plasma were saturating the BioPlex instrument.BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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VEGF protein was significantly (p < 0.05) increased in the
plasma of all atherosclerotic patients (Figure 2 and 3).
Steroid hormones and bone morphogenetic protein type II 
receptor (BMPR2)
The importance of pathways related to steroids in athero-
sclerosis is substantiated by a variety of data in our study.
The estrogen receptor ESR1, the progesterone receptor
PGRMC1 and the glucocorticoid receptor (GR) NR3C1
genes are down-regulated in the atherosclerotic coronaries
and NR3C1 also in carotids. In addition, we evidenced the
down-regulation of SUMO1 both in coronary and carotid
samples, and it is known that GR are activated by
sumoylation[13]. In this context, other important data are
the down-regulation of hormone sensitive lipase gene
(HSL or LIPE) and its interacting protein adipocyte fatty
acid-binding (AFABP) in both coronary and carotid
plaques. This has been confirmed by qRT-PCR evidencing
2.85 fold negative regulation of HSL in atherosclerotic
vessels. Although present, HSL may also be inactive
because the positive regulator of the 5'AMPK protein
PRKAB2 is under-expressed.
Since Donn R et al.[14] demonstrated the functional
interaction of glucocorticoid receptor with BMPR2, we
studied its expression by microarray and qRT-PCR evi-
dencing the down-regulation of this gene in both coro-
nary and carotid plaques (Figure 3). Actually, the whole
pathway controlled by BMPR2 is altered. For instance,
SMAD5 and ID4 genes, involved in BMPR2 signal trans-
duction, are down-regulated. Interleukin-6 (IL-6) and its
activation of STAT3 signaling contribute to the pulmonary
Functional interaction map of differentially expressed genes and proteins in atherosclerotic samples that are involved in lipid  homeostasis and caveolae system impairments Figure 3
Functional interaction map of differentially expressed genes and proteins in atherosclerotic samples that are 
involved in lipid homeostasis and caveolae system impairments. Arrow direction near gene symbols is related to its 
expression relative to control. Histograms represent log2 expression value relative to control gene, obtained by qRT-PCR for 
the indicated factors. White color bar means that gene expression was referred to GAPDH reference gene, grey to GUSB, 
graduated grey to HPRT1 and black to TBP. On the left side of the map is drawn the caveolae pathway with CAV-1 and CAV-
2 down-regulation connected to up-regulated VEGF. It is shown that associated hormone receptors and BMPR2 are down-reg-
ulated leading to ALOX5AP and LIPE down-regulation. In the central part of the map, the up-regulation of PLTP is connected 
to the loss of HDL concentration and to the accumulation of VLDL particles not hydrolyzed as a consequence of LPL down-
regulation. The right part of the diagram shows that clearance of LDL by MSR1 is impaired, but not that mediated by APOER. 
This may influence PDGF transduction which is related to SMC de-differentiation. Finally, the map connects the up-regulations 
of APOE, APOC and ABC transporters to the increased transcription of LXR.BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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arterial hypertension (PAH) related to BMPR2 down-reg-
ulation[15]. We found increased level of IL-6 mRNA in
coronary samples and of IL-6 protein in plasma of athero-
sclerotic patients (Figure 2). IL-6 is involved in the activa-
tion of JAK/STAT signaling pathway, which seems to be
critical for atherosclerotic plaque development[16]. This
pathway is generally enhanced in coronary and carotid
plaques as demonstrated by the up-regulation of STAT1,
a) Interaction network of genes/proteins differentially expressed in atherosclerotic arteries Figure 4
a) Interaction network of genes/proteins differentially expressed in atherosclerotic arteries. Interaction are 
described in the Additional file 1, Table S3; b) enlargement of the highly interconnected nodes of the interaction map showing 
the genes involved in the caveolae and steroid hormone receptor pathways. See text for discussion.BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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Interleukin 10 receptor and IFN-alpha-responsive tran-
scription factor subunit (ISGF3G). Also IL-2, -4, -5, -7 and
INF-gamma that are known activator of this pathway, are
more abundant in patients than in controls (Figure 2). In
addition, other genes belonging to this pathway are spe-
cifically up-regulated (TYK2, Sprouty 1 an inhibitor of the
Ras/MAPK pathway and SOCS1) or down-regulated
(PI3K, SOCS4 and leptin) in coronary samples.
Networks of deregulated genes/proteins in atherosclerotic 
samples
The functional analysis of atherogenes resulted in the con-
struction of a network of molecular interactions that is
presented in Figure 4a. The functional classification of
genes in the network is presented in the additional Figure
S2 (see Additional file 2, Figure S2). This highly intercon-
nected network could be subdivided in two large regions:
the first contains the down-regulated genes (left of Figure
4a) and the second the up-regulated genes (right of Figure
4a). Among the up-regulated genes, the functional catego-
ries of the cytokines (p-value 5.36 E-15) and chemokines
(p-value 2.32 E-4) are over-represented. This is in accord-
ance with results obtained by blood analysis that confirm
the presence of JAK/STAT induction factors and regulators
for the inflammatory process. The steroid hormone recep-
tor activity (p-value 6.9 E-8) and related functions, are
among the down-regulated genes. Analyzing at a finer
level the two regions of the map, it became clear that there
are five central nodes of interactions, enlarged in Figure
4b. The first is composed by genes of the caveolae system
connected to BMPR2, and the second node is composed
of hormone receptors. A third node is centered on STAT1
that is related to up-regulated members of HSP40 family,
interacting with HSP70, HSP40, HO-1 and HSP47. The
fourth node is composed by S100A8 and S100A9 genes
whose proteins are involved in inflammatory processes.
Finally, the fifth node points to the anti apoptotic gene
BCL2.
Discussion
As far as major factors influencing atherosclerotic traits are
concerned, our study was based on a homogeneous
cohort of patients. Patients and controls were matched for
age, as ageing influences the vascular substrate and the
development and progression of atherosclerosis. LAD
patients were 59 years old ± 9.7, while controls were 54.7
years ± 7.5. Datasets of gene expression in carotid plaques
were also obtained from patients with similar age. More-
over, all atherosclerotic patients had comparable stenosis.
Due to this homogeneity of experimental sources, the dif-
ferentially expressed genes that we have found should be
considered as generally involved in the molecular events
establishing and maintaining atherosclerosis.
The atherogenes network described in Figure 4, shows the
importance of both the inflammatory response and cave-
olae system, the first controlled by central node STAT1
(inducing also the over-expression of the heat shock pro-
teins HSP47[17] and HO-1), the second related to steroid
hormone receptors.
STATs are cytosolic proteins that, upon activation, translo-
cate in to the nucleus to activate target genes. Originally,
this pathway was found to be activated by INFs, but a
number of cytokines, growth factors, and hormonal fac-
tors were successively found as activators of JAK and/or
STAT proteins (see Additional file 2, Figure S3). In partic-
ular, INF-g activates STAT1 one of the central nodes of our
atherogene network (Figure 4) and this is in accordance
with the high level of the interferon protein found in
patients plasma (Figure 2). It is noteworthy that the anti-
inflammatory cytokine IL-10, which is not altered in the
patient blood, also activates JAK/STAT protein[18]. Its
receptor results among the up-regulated atherogenes (Fig-
ure 4), confirming the importance of this molecule in the
response to the pathological status to translate signals by
IL-10 molecule. These results confirm previous data
obtained in the atherosclerotic tissues but allow in addi-
tion the link between gene expression and plasma pro-
teins. The importance of the STAT, INFs and IL-10 signals
is strengthened by our results, since we were able to
detected it in atherosclerotic plaques of different vessels in
a series of 25 patients and 29 samples (Table 1).
Estrogen receptors (ESR) 1 and 2, expressed in normal and
atherosclerotic arteries, mediate the protective action of
estrogen to artery wall. ESR1 genotype is a predictor of
complex lesions, of coronary thrombosis, and has a role
in rising HDL cholesterol level[19]. Glucocorticoids and
their receptor (NR3C1) are also involved in atheroprotec-
tive effect. Our data suggest that the protective effect is
impaired by GR down-regulation in atherosclerotic
plaques from coronaries and carotid (Figure 3 and 4b).
The activation of HSL is compromised by the down-regu-
lation of both the hormone receptors and HSL activator
PRKAB2 (Figure 3). Decrease of adipocyte HSL activity has
been demonstrated in familial combined hyperlipidemia,
characterized by excessive concentrations of serum-free
fatty acids[20]. All patients showed an elevated choles-
terol concentration in the blood with index of cardiovas-
cular risk (total cholesterol concentration/HDL) ≥ 5 for
males and 4.5 for females.
Glucocorticoid receptor interacts with BMPR2[14], a com-
ponent of the TGFBR superfamily. BMPR2 is located
within caveolae of endothelial cell membranes suggesting
potential dynamic regulatory structural relationships[21]BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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lost in plaque (Figure 3 and 4b). BMPR2 gene defect is
involved in the development of pulmonary arterial hyper-
tension (PAH). PAH is characterized by the reduction of
the lumen of pulmonary arteries and serum IL-6 increase.
Additionally, IL-6 level was dramatically increased in
transgenic mice expressing a mutant BMPR2 which spon-
taneously developed PAH[22]. IL-6 is a cytokine with a
wide variety of biological functions. We focalized our
attention on its involvement in JAK/STAT pathway
because it appeared significantly compromised in both
coronary and carotid plaques (see Additional file 2, Figure
S3). It is considered a stress responsive signaling cascade,
involved in down-regulation of matrix genes[23] that
could promote plaque rupture. In fact, a reduced produc-
tion of collagen and its uncontrolled degradation may
affect the stability of the vessel wall especially in athero-
sclerotic plaques by making them prone to aneurysm and
rupture. Type IV, XV, XVIII and XIX collagens are structural
elements associated with the vascular basement mem-
branes. Each individual SMC is surrounded by a basement
membrane. Thus, all membrane-associated collagens are
probably involved in the regulation of intercommunica-
tion between vessel lumen and wall or between individual
SMCs in the intimal and medial layers. This intercommu-
nication appears to loosen in the coronaries and carotids,
and this probably leads to de-differentiation of SMC high-
lighted by down-regulation of CSRP2. This gene is highly
expressed in aorta and is drastically down-regulated in
response to PDGF-BB (Figure 3) or cell injury promoting
SMC proliferation and de-differentiation[24]. A domi-
nant-negative CSRP2 mutant blocked proepicardial cells
from differentiating into SMC[25]. The possible de-differ-
entiation of SMC is also supported by the down-regula-
tion of ACTA2 and PDLIM5 genes in both carotids and
coronaries. Proliferative effect of PDGF on SMC could be
inhibited by APOER which presents both a protective role
in the vasculature and an atherogenic function[26] (Fig-
ure 3). APOER up-regulation could balance de-differenti-
ative effects induced by PDGF on SMC, but could allow
SMC transformation to foam cells and impairment of ves-
sel structure. This correlation was already evidenced by
the work of King Y.J. et al.[6] but, in addition to this, we
have correlated the extracellular matrix with the expres-
sion of two important LIM proteins involved in the devel-
opment of muscle cells: CSRP2 and PDLIM5. These genes
could become important targets to modulate the effects of
the atherosclerotic lesion at its initial stage.
HDL mediate cholesterol clearance from foam cells but,
recently, raising HDL as a treatment for cardiovascular dis-
ease has been disputed because of the failure of the torce-
trapib therapy[27]. Despite this negative data, HDL-based
therapies such as reconstituted HDL, phospholipids and
APOA1Milano have shown some promising results focusing
the importance of lipids homeostasis in atherosclerosis.
LXR has a central role in the lipid homeostasis regulating
ABC transporter, PLTP and ApoE/C-I/C-IV-CII gene clus-
ter expression (Figure 3). Coronary and carotid gene
expression profiles evidenced the up-regulation of the
ABCC3 gene, a new member of the ATP-binding-cassette
family associated with atherosclerosis in mouse[28]. ABC
transporter regulates efflux of cholesterol and phospholi-
pids from peripheral tissues and macrophages mediating
reverse cholesterol transport (RCT). RCT is considered to
be the primary mechanism through which HDL protects
against atherosclerosis, but its production is limited in
LAD patients by LPL down-regulation and PLTP up-regu-
lation. Moreover, the index of cardiovascular risk was ≥ 5
and 4.5 for males and females respectively indicating low
HDL in patient blood. PLTP over-expression appears to be
connected to a decrease of HDL and to an increase of
ApoE that prevents its inactivation. PLTP has been already
identified like one of the "candidate genes" for atheroscle-
rosis[29,30] and this is confirmed by our meta-analysis.
On the other hand LPL is an enzyme present in capillary
surface, and lack of it causes familial hyperlipoproteine-
mia type I, characterized by massive hypertriglyceridemia.
The impairment of the lipolysis process could support low
HDL production by this pathway.
Fatty acids and lipoproteins are removed from circulation
by scavenger receptors. CD36 and MSR1 genes are down-
regulated in atherosclerotic vessels and this could contrib-
ute to the impairment of clearance process and cause the
elevated values in the analyzed patients (Table 1). CD36 is
a scavenger receptor for modified forms of LDL and its loss
leads to a pro-atherogenic lipid profile in mice[31] while
MSR1 scavenger increases clearance of modified lipopro-
teins, protecting the arterial wall against the pro-athero-
genic action of LP[32]. The down-regulation of CD36 and
MSR1 could result in a increasing of atherosclerotic lesion
in vessel as it was demonstrated in studies on SR-BI-/- ApoE-
/-  mouse model with microdeletions in scavenger
genes[33]. Our data are coherent with the dyslipidemia of
atherosclerotic patients (Figure 3) that could be associated
with the subsequent development of hypertension causing
damage to the inner walls of arteries. These data could
apparently appear in contrast with the supposed pro-ather-
ogenic function of CD36. However this protein could play
very different roles due to the variety of functions that have
been associated to it. In fact, it is involved also in the regu-
lation of the angiogenesis in association with throm-
bospondin (TSP)[34]. Angiogenesis is the body response to
ischemia and vascular injury and is inhibited by the inter-
action of CD36 with TSP-1. CD36-TSP-1 interaction is also
important in the maintenance of an anti-inflammatory
milieu in the uptake of apoptotic cells as a homeostatic
process, and during wound resolution. The down regula-BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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tion of CD36 may be also important to maintain the ability
of producing novel vessels important for the plaque main-
taining supplying nutrition to grow[35].
CD36 and SR are related to Caveolin-1 (Cav-1)[36] which
is a cholesterol-binding protein transporting cholesterol
from the endoplasmic reticulum to the plasma mem-
brane. Before this work, there was limited evidence of
altered Cav-1 levels in human atherosclerotic lesions[37].
Loss of caveolin-1 in ApoE-/- mouse resulted in a pro-
atherogenic lipid profile, similar to that seen in CD36-/-
mice bread to an ApoE background[31]. Absence of Cav-
1 and caveolae in endothelial cell (EC) lead to increased
eNOS activity and NO release, resulting in reduced vascu-
lar tone[38]. Furthermore, Caveolin-1 is a negative regula-
tor of EC proliferation but promotes cellular
differentiation[38]. However, angiogenic factors such as
VEGF have been shown to induce down-regulation of
caveolin-1, which was suggested to be important for the
mitogenic effects of growth factors in EC[38,39]. Caveolin
genes down-regulation therefore could lead to decreased
inhibition of EC proliferation and to a negative effect on
SMC differentiation. Dyslipidemia evidenced in Cav-1-/-
and CD36-/-  mice is congruent once more with our
hypothesis on involvement of Caveolin genes in the con-
trol of cholesterol homeostasis.
In summary, the analysis of the atherogenes network that
we have outlined shows that the atherosclerotic pheno-
type of arterial vessels is maintained by altered pathways
of hormone receptors, lipid homeostasis and caveolae sys-
tem that are highly interconnected through specific nodal
genes. This is a novel interconnection evidenced in the
atherosclerotic plaque that has been confirmed in differ-
ent patients (different genetic background) and different
atherosclerotic sites. Before our work, there were no evi-
dences for the relationship between caveolae, BMPR2 and
hormone receptor genes that are in turn related, in our
network, to genes involved in the apoptotic process (Fig-
ure 4). The involvement of the caveolae system in human
lipid homeostasis and atherosclerosis has been con-
firmed. This is a central node linking the network of down
regulated genes (left in Figure 4) to the up regulated one
(right in Figure 4). This connection is sustained by APP
(amyloid beta precursor protein) and APOE, previously
discussed. Perhaps it should be considered the possibility
that amyloid-β (Aβ) might be involved in vascular pathol-
ogy. In fact, APP is involved in blood clotting[40] and Aβ
drains from the brain along the walls of the microvascula-
ture[41]. Down regulation of APP gene could be involved
in thrombosis effect[40] related to the advanced status
and unstable condition of the plaques studied in this
work (Figure 1).
The portion of the network with over expressed genes is
characterized by the inflammatory response regulated by
JAK/STAT pathway and is integrated by the data on
plasma proteins involved in this process. These data con-
firm the known involvement of JAK/STAT pathway in
atherosclerosis, but our study has validated for the first
time the common deregulation of these genes in different
atherosclerotic sites and correlated to the hormone recep-
tor, caveolae system and APP connected to the instability
of the plaque.
Conclusion
Atherosclerosis affects aorta, coronary, carotid, and iliac
arteries most frequently than any other body vessel. Our
study aimed to the description of common molecular
pathways sustaining this process, integrating data
obtained by gene expression profiling of human athero-
sclerotic vessels and by parallel measuring of blood circu-
lating factors.
We were able to define a network of functionally con-
nected genes that are commonly altered in atherosclerotic
vessels (human "atherogenes"). These pathways and
genes could be useful information for the development of
new drugs against imbalance of cholesterol homeostasis
and hypertension. Interesting potential targets could be
PLTP and BMPR2 genes.
Methods
Patient characterization and tissue sampling
For this study 31 patients were recruited among those sub-
jected to heart transplantation for ischemic cardiomyopa-
thy (ICM) or dilated cardiomyopathy (DCM) at the
Cardiovascular Surgical Unit of the University of Verona
Medical School. On the basis of clinical diagnosis and
angiography, patients were divided in atherosclerotic
(with 75% stenosis of one coronary artery at least), and
non-atherosclerotic controls (Table 1).
Immediately after cardiotomy, left anterior descendent
(LAD) coronaries were dissected from diseased hearts,
cleaned from fatty and cardiac muscle tissues, and stored in
RNAlater Solution (Ambion). 5-μm-thick serial sections of
paraffin-included coronary fragments were used for histol-
ogy. All atherosclerotic lesions were classified as type VI or
VII according to the criteria proposed by the American Heart
Association[9]. Typically, type VI lesions were characterized
by one or more surface defect, hematoma and thrombosis,
while calcification prevailed in type VII plaques.
Arterial blood from atherosclerotic and non-atheroscle-
rotic individuals was collected, before anti-coagulant
administration, in BD Vacutainer CPT cell preparation
tubes, and processed according to manufacturer's direc-
tions. We recovered blood in the vicinity of the atheroscle-
rotic plaque in order to evaluate factors released from the
plaque and cells in the surrounding area. Blood was recov-BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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ered from the pulmonary artery of patients after anesthe-
sia and before administration of anti-coagulants.
The ethical committee approved the study and written
informed consent was obtained from all the participants
after exhaustive information on the study.
Coronary RNA extraction and gene expression experiments
Visible plaques, adjacent to the segment utilized for histolog-
ical analysis, were dissected from the entire coronary frag-
ment and used for total RNA extraction with TRIzol
(Invitrogen). RNA was prepared also from 10 non-athero-
sclerotic coronaries, pooled and utilized as a common con-
trol sample. Control RNA pool and plaque RNAs (1 μg) were
linearly amplified with MessageAmp™ aRNA amplification
kit (Ambion), labeled with Cy3 and Cy5 dye (Amersham)
and competitively hybridized to oligonucleotide microar-
rays platforms (GEO ID: GPL6647). For each sample we per-
formed two microarray experiments at least. Microarrays
were read with the ScanArray LITE confocal laser scanner
(PerkinElmer). Each slide was subjected to three consecutive
scans at low, medium and high settings of laser and photo-
multiplier[42]. We therefore produced six 16-bit images per
microarray, grouped in low, intermediate and high intensity
scans. Images were quantified with ScanArray Express soft-
ware (PerkinElmer). Data were normalized using the total
and lowess methods, implemented in the MIDAW tool[43]
and submitted to GEO database (GSE11138). Data filtering
was made as outlined in the Additional file 3. For each group
of images obtained with different laser power, the genes with
expression values in all experiments were analyzed by SAM
program[44] implemented in the TMEV software[45]. SAM
identifies statistically significant changes in gene expression
by applying a modified t-test and controlling false discovery
through a permutation technique. We performed 100
rounds of such permutations. Finally, the lists of differen-
tially expressed genes presenting false discovery rate of 0
were integrated[42].
Meta-analysis
To compare our expression data with published expression
profiles, we applied a meta-analysis approach to expression
datasets of 8 carotid samples taken from Array Express data-
base (E-MEXP-268) and 6 coronary controls retrieved from
Gene Expression Omnibus (GSE3526, GSE7307), using row
data only[46]. Normal coronary profiles were used as com-
mon reference for carotid plaque expression data, since no
important differences emerged from the comparison
between normal carotid and normal coronary expression
profiles (data not shown). Moreover, since the characteristics
of peripheral arteries, like thickness of intima-media layers of
carotid wall, are used as surrogate markers for coronary
atherosclerosis, we decided to compare directly gene expres-
sion of these two vessels. However, since it is known that
atherosclerosis show some rate of artery-dependent pat-
terns[47], it should be clarified that the comparison of dis-
eased carotids to normal coronaries could result in some
grade of under- or overestimation of differences in gene
expression. Briefly, data have been normalized using the
invariant probe set normalization method[48], imple-
mented in d-chip software, and matched for the common
probe set between the different platforms used in the experi-
ments. Differentially expressed genes were calculated from
normalized values by applying the fold change and t-test
methods.
The lists of genes differentially expressed in atheroscle-
rotic coronaries and carotids were compared using the
identification of Entrez Gene database and matching
entries were classified as "atherogenes" (see the Results).
Coronary specific, carotid specific and common differen-
tially expressed genes have been functionally classified
using Gene Ontology criteria as implemented in
DAVID[49] and used to build networks of functionally
correlated genes/protein by Cytoscape[50]. Cytoscape is
an open source bioinformatic platform for visualizing
molecular interaction networks and biological pathways.
To retrieve interactions between differentially expressed
genes and to construct the larger general interaction net-
work (Figure 4a), we used the Biomolecular Interaction
Network Database (BIND) http://bond.unleashedinfor
matics.com/index.jsp?pg=0, that is a collection of records
documenting protein interaction, molecular complexes
and pathways. We also made use of the Biological General
Repository for Interaction Datasets (BioGRID) database
http://www.thebiogrid.org[51] developed at the Univer-
sity of Toronto (Canada) to house and distribute collec-
tions of proteins and genetic interactions from major
model organisms. This larger network was used to identify
high interconnected nodes with the MCODE[52] Cyto-
scape plug-in. MCODE is an algorithm that allows the
finding of clusters in interaction networks to evidence
protein complexes or related pathways. Parameters used
for MCODE were: Score 1.80, Nodes 76 and 170 Edges.
The MCODE defines score as the product of the complex
sub-graph density and the number of vertices in the com-
plex sub-graph. With this process MCODE assigns higher
values to large node and dense complexes. The inferred
sub-network displayed in Figure 4b was that classified
with the highest score.
Functional classification of genes connected in the larger
network (Figure 4a) was done according to Gene Ontol-
ogy (GO) using the Cytoscape plug-in BINGO[53]. This is
a bioinformatic tool able to determine which GO catego-
ries are statistically overrepresented in a set of genes or a
sub-graph of a biological network. We used a hypergeo-
metric test and the Benjamini and Hochberg False Discov-
ery rate (FDR) correction with 0.05 level of significance.
The results are plotted in the additional Figure S2 (see
Additional file 2, Figure S2).BMC Genomics 2009, 10:13 http://www.biomedcentral.com/1471-2164/10/13
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Quantitative real-time PCR
Equal aliquots of aRNA from each sample were mixed and
400 ng of this pool were used for first strand cDNA syn-
thesis using Superscript II (Invitrogen). Four independent
reactions were carried out, pooled and used for qRT-PCR
with SYBR green. Each qRT-PCR was performed in tripli-
cate using the 7500 Real Time PCR System (Applied Bio-
systems), and analyzed according the Pfaffl method[54].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
glucuronidase beta (GUSB), TATA box binding protein
(TBP) and hypoxanthine phosphoribosyltransferase 1
(HPRT1) were used as reference transcripts. Sequences of
the primers used for qRT-PCR of various mRNA are
reported in the additional Table S1 (see Additional file 1,
Table S1).
Blood plasma analysis
Plasma was used to analyze cytokine and growth factors
concentration using the Bioplex instrumentation (Bio-
Rad). We used the human cytokine 27-plex panel accord-
ing to the manufacturer's specificity.
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